Adjuvant Abemaciclib
from OncoPharm Hosted by John Bossaer
FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel. NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of OncoPharm?
This episode is 16 minutes long.
When was this OncoPharm episode published?
This episode was published on October 14, 2021.
Can I download this OncoPharm episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.